Drug
KHK4083 clinical trials
Also written AMG 451, Rocatinlimab and KHK4083.
- studies test it
- 18
- open now
- 0
- in phase 3
- 9
- first study started
- 2016
How studies write it
Studies that test it under each name
Studies by the year they started
18 studies that test it; most in 2023 (6)
| Year | Studies |
|---|---|
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2022 | 2 |
| 2023 | 6 |
| 2024 | 6 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 5
- Phase 2
- 3
- Phase 3
- 9
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 18 · Other 0
Amgen (14) · Kyowa Kirin, Inc. (2) · Kyowa Kirin Co., Ltd. (2)
Studies
Open first, then newest update. How each study uses KHK4083 is read from its arms, and is right about nine times in ten.
Testing it · 18
- A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy ParticipantsCompletedPhase 1AmgenNCT06268860Written as Rocatinlimab vial injection
- A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)CompletedPhase 3AmgenNCT05704738Written as Rocatinlimab
- A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe AsthmaTerminatedPhase 2AmgenNCT06376045Written as Rocatinlimab
- A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)CompletedPhase 3AmgenNCT05724199Written as Rocatinlimab
- A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo NodularisTerminatedPhase 3AmgenNCT06527404Written as Rocatinlimab
- A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)CompletedPhase 3AmgenNCT05633355Written as Rocatinlimab
- A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)CompletedPhase 3AmgenNCT05899816Written as Rocatinlimab
- A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)CompletedPhase 3AmgenNCT05398445Written as Rocatinlimab
- A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)TerminatedPhase 3AmgenNCT05882877Written as Rocatinlimab
- A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)CompletedPhase 3AmgenNCT05651711Written as Rocatinlimab
- A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic DermatitisCompletedPhase 3AmgenNCT06224192Written as Rocatinlimab Prefilled Syringe
- A Study to Evaluate Bioavailability of Rocatinlimab Autoinjector and Vial in Healthy ParticipantsCompletedPhase 1AmgenNCT06438263Written as Rocatinlimab
- A Study to Evaluate Rocatinlimab (AMG 451) in Healthy Chinese ParticipantsCompletedPhase 1AmgenNCT06214481Written as Rocatinlimab
- Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic DermatitisCompletedEarly Phase 1AmgenNCT05891119Written as Rocatinlimab
- Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative ColitisCompletedPhase 2Kyowa Kirin, Inc.NCT02647866Written as KHK4083
- Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic DermatitisCompletedPhase 2Kyowa Kirin, Inc.NCT03703102Written as KHK4083
- A Phase 1 Study of KHK4083 in Healthy Volunteers and Subjects With Ulcerative ColitisCompletedPhase 1Kyowa Kirin Co., Ltd.NCT02985593Written as KHK4083
- A Phase 1 Study of KHK4083 in Subjects With Atopic DermatitisCompletedPhase 1Kyowa Kirin Co., Ltd.NCT03096223Written as KHK4083
Codes
What other systems call KHK4083 · ClinicalTrials.gg INT000949
- MeSH (NLM) C000627613KHK4083One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000627613 | KHK4083 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.